J&J Reports 2.4% Stake in Nanobiotix S.A. as of Dec 31, 2023

Ticker: JNJ · Form: SC 13G/A · Filed: 2024-02-02T00:00:00.000Z

Sentiment: neutral

Topics: insider-ownership, amendment, pharmaceuticals

TL;DR

**J&J still holds 2.4% of Nanobiotix, watch for potential future collaboration.**

AI Summary

Johnson & Johnson (J&J) filed an amended SC 13G/A on February 2, 2024, disclosing its ownership in Nanobiotix S.A. as of December 31, 2023. J&J, a pharmaceutical giant, reported beneficial ownership of 1,000,000 Ordinary Shares of Nanobiotix, representing 2.4% of the company's outstanding shares. This filing indicates J&J's continued, albeit minor, strategic interest in Nanobiotix, a French pharmaceutical preparations company, which could signal potential future collaborations or a deeper partnership, making it relevant for investors watching J&J's strategic moves in the biotech space.

Why It Matters

This filing confirms Johnson & Johnson's ongoing investment in Nanobiotix, a company focused on pharmaceutical preparations, which could influence Nanobiotix's stock performance and future strategic direction.

Risk Assessment

Risk Level: low — This is an amendment to a passive ownership filing, indicating no significant change in control or immediate risk.

Analyst Insight

Investors should note J&J's continued, albeit small, stake in Nanobiotix, which could be a long-term strategic play. While not an immediate catalyst, it's a data point for those tracking J&J's biotech interests or Nanobiotix's potential for future partnerships.

Key Numbers

1,000,000 — Ordinary Shares (Number of Nanobiotix shares beneficially owned by Johnson & Johnson.)
2.4% — Ownership Percentage (Percentage of Nanobiotix's Ordinary Shares beneficially owned by Johnson & Johnson.)
December 31, 2023 — Reporting Date (The date as of which the ownership information was reported.)

Key Players & Entities

Johnson & Johnson (company) — the reporting person and beneficial owner
Nanobiotix S.A. (company) — the issuer of the securities
1,000,000 (dollar_amount) — number of Ordinary Shares beneficially owned by J&J
2.4% (dollar_amount) — percentage of Nanobiotix's class of securities beneficially owned by J&J
December 31, 2023 (date) — date of the event requiring the filing

Forward-Looking Statements

Johnson & Johnson will maintain its passive stake in Nanobiotix S.A. for the foreseeable future. (Johnson & Johnson) — medium confidence, target: December 31, 2024
Nanobiotix S.A. may see increased investor interest due to Johnson & Johnson's continued ownership. (Nanobiotix S.A.) — low confidence, target: June 30, 2024

FAQ

What is the purpose of this SC 13G/A filing by Johnson & Johnson?

This SC 13G/A is an amendment (Amendment No. 1) to a Schedule 13G filing, indicating an update to Johnson & Johnson's beneficial ownership of Nanobiotix S.A. securities as of December 31, 2023, filed pursuant to Rule 13d-1(c).

Which company's shares are being reported in this filing?

The filing reports on the Ordinary Shares, €0.03 nominal value per share, of Nanobiotix S.A. (CUSIP Number 63009J107*).

What percentage of Nanobiotix S.A. does Johnson & Johnson beneficially own according to this filing?

Johnson & Johnson beneficially owns 2.4% of the class of securities of Nanobiotix S.A., specifically 1,000,000 Ordinary Shares.

What was the 'Date of Event Which Requires Filing of this Statement'?

The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as stated in the filing.

Under which rule was this Schedule 13G filed?

This Schedule 13G was filed under Rule 13d-1(c), as indicated by the checked box in the filing.

From the Filing

0000904454-24-000092.txt : 20240202 0000904454-24-000092.hdr.sgml : 20240202 20240202163227 ACCESSION NUMBER: 0000904454-24-000092 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Nanobiotix S.A. CENTRAL INDEX KEY: 0001760854 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-91935 FILM NUMBER: 24592027 BUSINESS ADDRESS: STREET 1: 60 RUE DE WATTIGNIES CITY: PARIS STATE: I0 ZIP: 75012 BUSINESS PHONE: 33140260470 MAIL ADDRESS: STREET 1: 60 RUE DE WATTIGNIES CITY: PARIS STATE: I0 ZIP: 75012 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: JOHNSON & JOHNSON CENTRAL INDEX KEY: 0000200406 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 221024240 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 BUSINESS PHONE: 732-524-2455 MAIL ADDRESS: STREET 1: ONE JOHNSON & JOHNSON PLZ CITY: NEW BRUNSWICK STATE: NJ ZIP: 08933 SC 13G/A 1 s13ga_011924-nanobiotix.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1) 1 Nanobiotix S.A. (Name of Issuer) Ordinary Shares, €0.03 nominal value per share (Title of Class of Securities) 63009J107* (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) * This CUSIP Number applies to the Issuer’s American Depositary Shares, each representing one Ordinary Share. No CUSIP Number has been assigned to the Ordinary Shares. Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [X] Rule 13d-1(c) [ ] Rule 13d-1(d)	 1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP No. 63009J107 13G Page 2 of 5 1. NAME OF REPORTING PERSON Johnson & Johnson 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION New Jersey NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER -0- 6. SHARED VOTING POWER 5,623,816 (1) 7. SOLE DISPOSITIVE POWER -0- 8. SHARED DISPOSITIVE POWER 5,623,816 (1) 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,623,816 (1) 10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)	 11.9% (2) 12. TYPE OF REPORTING PERSON CO (1) Held as American Depositary Shares, each representing one Ordinary Share. (2) Based on 47,133,328 Ordinary Shares outstanding as of December 31, 2023, as reported in the Issuer’s Report on Form 6-K filed with the Securities and Exchange Commission on January 12, 2024. CUSIP No. 63009J107 13G Page 3 of 5 1. NAME OF REPORTING PERSON Johnson & Johnson Innovation-JJDC, Inc. 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTIN